{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-051251","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-07-31T12:48:17+00:00","discovered_at":"2026-07-31T12:50:00.314271+00:00","generated_at":"2026-07-31T12:50:05.066112+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Vistagen appoints Douglas J. Williamson, M.D. to Board of Directors","bullets":["Dr. Williamson appointed to Vistagen's Board effective July 29, 2026.","He received options to purchase 40,826 shares at $0.2433, vesting over three years.","Williamson brings 30 years of neuroscience drug development and regulatory experience.","He previously served as CMO of QurAlis, EVP R&D at Acadia, and senior roles at Lundbeck and Eli Lilly.","He will serve until the next annual meeting or until successor is elected."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-051251","json":"https://secwatch.observer/filing/0001628280-26-051251.json","markdown":"https://secwatch.observer/filing/0001628280-26-051251.md","text":"https://secwatch.observer/filing/0001628280-26-051251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026051251/0001628280-26-051251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026051251/vtgn-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T12:50:05.066112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}